Phase 3 RCT in 423 patients with MYC/BCL2 double-expressor DLBCL: tucidinostat plus R-CHOP improved event-free survival vs placebo plus R-CHOP (HR 0.72; 2-year EFS 60.3% vs 50.5%), with increased but manageable toxicity.
RCTn = 423
Xu et al. Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma: A Randomized Clinical Trial